Cel-Sci Corp (CVM)

$6.29 +0.33 (5.54%)
Market Cap 55.55M
Revenue (ttm) 0.00
Net Income (ttm) -26.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 54,380
Avg Vol 79,752
Day's Range N/A - N/A
Shares Out 8.02M
Stochastic %K 33%
Beta 0.49
Analysts Strong Sell
Price Target $180.18

Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune syste...

Industry: Biotechnology
Sector: Healthcare
Phone: 703 506 9460
Website: cel-sci.com
Address:
8229 Boone Boulevard, Suite 802, Vienna, United States
Cruiser24
Cruiser24 Dec. 5 at 9:35 AM
$CVM You hit the nail on the head. He does every poster with positive narrative the same way. He is an incorrigible person. Good Luck Bulls. Know what you own. 💎🤚✋💎
0 · Reply
Cruiser24
Cruiser24 Dec. 5 at 9:09 AM
$CVM BULLISH I have also made a comment similar to yours after watching one of his interviews on Utube. Rather than concentrating on the question of Geert’s sobriety I think it more important to remember all their good we see happening in the CVM organization. That is if you are a Bull invested in CVM. The insider trades made since August,this filing and other recent filings, the Confirmatory and MOU with Dallas-pharma, and last but not least the predefined sub group statistics published in a medical journal showing relative improvement in OS and quality of life without any outstanding safety issues are what keep me 💎🤚✋💎. And as always this is IMHO and not intended as financial advice. Everyone should do their own due diligence, keeping in mind there are many different ways to trade CVM. There are longs, shorters, day traders, etc., and they all have their many varying and yes opposite opinions to which they speak. Know what you have invested in and why. As for myself. As always. 💎🤚✋💎
0 · Reply
Cruiser24
Cruiser24 Dec. 5 at 8:41 AM
$CVM BULLISH I would love to hear that answer. There are a lot on this board that don’t want anything positive about CVM commented on this board. All they can do is insult the poster and talk negativity about the CEO. They refuse to admit there is more to CVM than the CEO. They want anyone that brings information,as yours, banned from this site. They want to dominate the narrative. And all their narrative is and always is negative. Thank you for sharing. GAOOD luck Bulls. Know what you own.💎✋🤚💎
0 · Reply
Cruiser24
Cruiser24 Dec. 5 at 8:32 AM
$CVM BULLISH Nice pic. May I use it? It would work great to display my thoughts if done others on this board. IMMX is definitely one of them. News yesterday just verifies IMO CVM is working in the background to get Multikine to the market. As always 💎🤚✋💎 @Cruiset24
0 · Reply
DeepThought
DeepThought Dec. 5 at 5:41 AM
$NWBO $CVM $IMMX You are Sushi? I don’t have any good memories of you. If you’re so proud of your former self, why don’t you post under Sushi? Well, this is the bitter realization: sometimes you’re just nothing more than an asshole."
1 · Reply
ImmxBeliever
ImmxBeliever Dec. 5 at 5:19 AM
$CVM $NWBO Wow. I triggered @DeepThought He hasn’t had an original idea yet. Big 💎🙏 gal 🤣🤣🤣
1 · Reply
DeepThought
DeepThought Dec. 5 at 5:09 AM
$CVM
0 · Reply
ImmxBeliever
ImmxBeliever Dec. 5 at 4:54 AM
$NWBO $CVM Amazing how many of the same morons, and I mean real morons, are in both these scams. Everyone a 💎🙏 It’s always the Shorts that are the problem. Dark pools The corrupt FDA Biden Adam Feuerstein Big Pharma preventing the success of these stocks Never your fault for ignoring red flags Never your fault for not knowing how to read financials, specifically Cash Flow stmt, filings. All you will lose it all and blame everyone but yourself! Cheers
1 · Reply
DeepThought
DeepThought Dec. 5 at 4:00 AM
$CVM 🤡Clown🤡
0 · Reply
MacArt28
MacArt28 Dec. 5 at 12:41 AM
$CVM So I post accurate info (that the SEC’s Notice of Effectiveness is linked by file # to the Ergomed deal for 375k shares) and @ImmxBeliever BLOCKS ME! Is that bc he doesn’t want accurate info or bc he doesn’t want me TO SEE (or respond) to the BS he constantly spews on this board???
1 · Reply
Latest News on CVM
CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025

Oct 20, 2025, 9:00 AM EDT - 6 weeks ago

CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025

CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference

Oct 10, 2025, 8:00 AM EDT - 7 weeks ago

CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference

CEL-SCI Announces Closing of $10 Million Public Offering

Aug 29, 2025, 12:52 PM EDT - 3 months ago

CEL-SCI Announces Closing of $10 Million Public Offering

CEL-SCI Announces Pricing of $10 Million Public Offering

Aug 27, 2025, 10:35 PM EDT - 3 months ago

CEL-SCI Announces Pricing of $10 Million Public Offering

CEL-SCI Announces Proposed Public Offering

Aug 27, 2025, 5:25 PM EDT - 3 months ago

CEL-SCI Announces Proposed Public Offering

CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results

Aug 14, 2025, 10:45 AM EDT - 4 months ago

CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results

CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline

Aug 13, 2025, 9:15 AM EDT - 4 months ago

CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

Jul 14, 2025, 4:05 PM EDT - 5 months ago

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules

Jul 11, 2025, 12:16 PM EDT - 5 months ago

CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

Jul 11, 2025, 9:15 AM EDT - 5 months ago

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

Jun 18, 2025, 9:00 AM EDT - 6 months ago

FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

CEL-SCI Announces Closing of Public Offering

May 23, 2025, 4:05 PM EDT - 6 months ago

CEL-SCI Announces Closing of Public Offering

CEL-SCI Announces Pricing of Public Offering

May 21, 2025, 8:14 PM EDT - 7 months ago

CEL-SCI Announces Pricing of Public Offering

CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia

May 21, 2025, 8:00 AM EDT - 7 months ago

CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia

CEL-SCI Announces Combination of Common Stock

May 19, 2025, 2:40 PM EDT - 7 months ago

CEL-SCI Announces Combination of Common Stock

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

May 15, 2025, 9:00 AM EDT - 7 months ago

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

Apr 23, 2025, 8:30 AM EDT - 8 months ago

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

Apr 8, 2025, 9:51 AM EDT - 8 months ago

New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

Mar 24, 2025, 9:00 AM EDT - 9 months ago

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

CEL-SCI Announces Closing of $2.5 Million Offering

Mar 18, 2025, 4:05 PM EDT - 9 months ago

CEL-SCI Announces Closing of $2.5 Million Offering

CEL-SCI Announces Pricing of $2.5 Million Offering

Mar 17, 2025, 3:24 PM EDT - 9 months ago

CEL-SCI Announces Pricing of $2.5 Million Offering

CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

Mar 17, 2025, 8:00 AM EDT - 9 months ago

CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

Mar 14, 2025, 8:30 AM EDT - 9 months ago

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

Feb 20, 2025, 8:00 AM EST - 10 months ago

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

Feb 18, 2025, 8:30 AM EST - 10 months ago

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

Jan 14, 2025, 9:00 AM EST - 11 months ago

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

CEL-SCI Announces Closing of $5 Million Offering

Dec 31, 2024, 4:05 PM EST - 1 year ago

CEL-SCI Announces Closing of $5 Million Offering

CEL-SCI Announces Pricing of $5 Million Public Offering

Dec 29, 2024, 8:41 PM EST - 1 year ago

CEL-SCI Announces Pricing of $5 Million Public Offering

CEL-SCI Announces Proposed Public Offering of Common Stock

Dec 27, 2024, 5:05 PM EST - 1 year ago

CEL-SCI Announces Proposed Public Offering of Common Stock

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

Dec 12, 2024, 9:15 AM EST - 1 year ago

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

Stock Picks From Seeking Alpha's October 2024 New Analysts

Nov 8, 2024, 8:00 AM EST - 1 year ago

Stock Picks From Seeking Alpha's October 2024 New Analysts

ACGL AMCX AMPS APOG AVRE BHP BILL

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

Nov 7, 2024, 8:15 AM EST - 1 year ago

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

Oct 22, 2024, 9:15 AM EDT - 1 year ago

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

Oct 1, 2024, 6:00 AM EDT - 1 year ago

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

Sep 16, 2024, 7:30 AM EDT - 1 year ago

CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

Sep 10, 2024, 9:32 AM EDT - 1 year ago

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

Sep 4, 2024, 9:00 AM EDT - 1 year ago

The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

Aug 15, 2024, 8:00 AM EDT - 1 year ago

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

CEL-SCI Announces Closing of $10.8 Million Offering

Jul 29, 2024, 4:05 PM EDT - 1 year ago

CEL-SCI Announces Closing of $10.8 Million Offering

CEL-SCI Announces Pricing of $10.8 Million Offering

Jul 26, 2024, 11:52 AM EDT - 1 year ago

CEL-SCI Announces Pricing of $10.8 Million Offering

CEL-SCI's Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results

Jul 26, 2024, 8:23 AM EDT - 1 year ago

CEL-SCI's Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results

CEL-SCI Appoints Robert Watson as Chairperson of the Board

Jul 8, 2024, 9:15 AM EDT - 1 year ago

CEL-SCI Appoints Robert Watson as Chairperson of the Board

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population

Jun 18, 2024, 8:00 AM EDT - 1 year ago

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results

May 16, 2024, 9:00 AM EDT - 1 year ago

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer

May 8, 2024, 9:00 AM EDT - 1 year ago

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer

CEL-SCI Appoints Mario Gobbo to Its Board of Directors

Apr 23, 2024, 9:00 AM EDT - 1 year ago

CEL-SCI Appoints Mario Gobbo to Its Board of Directors

Channel V Media Expands Content Marketing Division; Names Gabriella Bock Director of Content

Apr 16, 2024, 9:00 AM EDT - 1 year ago

Channel V Media Expands Content Marketing Division; Names Gabriella Bock Director of Content

CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

Mar 19, 2024, 9:00 AM EDT - 1 year ago

CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

CEL-SCI Corporation Issues Letter to Shareholders

Mar 6, 2024, 8:45 AM EST - 1 year ago

CEL-SCI Corporation Issues Letter to Shareholders

Cruiser24
Cruiser24 Dec. 5 at 9:35 AM
$CVM You hit the nail on the head. He does every poster with positive narrative the same way. He is an incorrigible person. Good Luck Bulls. Know what you own. 💎🤚✋💎
0 · Reply
Cruiser24
Cruiser24 Dec. 5 at 9:09 AM
$CVM BULLISH I have also made a comment similar to yours after watching one of his interviews on Utube. Rather than concentrating on the question of Geert’s sobriety I think it more important to remember all their good we see happening in the CVM organization. That is if you are a Bull invested in CVM. The insider trades made since August,this filing and other recent filings, the Confirmatory and MOU with Dallas-pharma, and last but not least the predefined sub group statistics published in a medical journal showing relative improvement in OS and quality of life without any outstanding safety issues are what keep me 💎🤚✋💎. And as always this is IMHO and not intended as financial advice. Everyone should do their own due diligence, keeping in mind there are many different ways to trade CVM. There are longs, shorters, day traders, etc., and they all have their many varying and yes opposite opinions to which they speak. Know what you have invested in and why. As for myself. As always. 💎🤚✋💎
0 · Reply
Cruiser24
Cruiser24 Dec. 5 at 8:41 AM
$CVM BULLISH I would love to hear that answer. There are a lot on this board that don’t want anything positive about CVM commented on this board. All they can do is insult the poster and talk negativity about the CEO. They refuse to admit there is more to CVM than the CEO. They want anyone that brings information,as yours, banned from this site. They want to dominate the narrative. And all their narrative is and always is negative. Thank you for sharing. GAOOD luck Bulls. Know what you own.💎✋🤚💎
0 · Reply
Cruiser24
Cruiser24 Dec. 5 at 8:32 AM
$CVM BULLISH Nice pic. May I use it? It would work great to display my thoughts if done others on this board. IMMX is definitely one of them. News yesterday just verifies IMO CVM is working in the background to get Multikine to the market. As always 💎🤚✋💎 @Cruiset24
0 · Reply
DeepThought
DeepThought Dec. 5 at 5:41 AM
$NWBO $CVM $IMMX You are Sushi? I don’t have any good memories of you. If you’re so proud of your former self, why don’t you post under Sushi? Well, this is the bitter realization: sometimes you’re just nothing more than an asshole."
1 · Reply
ImmxBeliever
ImmxBeliever Dec. 5 at 5:19 AM
$CVM $NWBO Wow. I triggered @DeepThought He hasn’t had an original idea yet. Big 💎🙏 gal 🤣🤣🤣
1 · Reply
DeepThought
DeepThought Dec. 5 at 5:09 AM
$CVM
0 · Reply
ImmxBeliever
ImmxBeliever Dec. 5 at 4:54 AM
$NWBO $CVM Amazing how many of the same morons, and I mean real morons, are in both these scams. Everyone a 💎🙏 It’s always the Shorts that are the problem. Dark pools The corrupt FDA Biden Adam Feuerstein Big Pharma preventing the success of these stocks Never your fault for ignoring red flags Never your fault for not knowing how to read financials, specifically Cash Flow stmt, filings. All you will lose it all and blame everyone but yourself! Cheers
1 · Reply
DeepThought
DeepThought Dec. 5 at 4:00 AM
$CVM 🤡Clown🤡
0 · Reply
MacArt28
MacArt28 Dec. 5 at 12:41 AM
$CVM So I post accurate info (that the SEC’s Notice of Effectiveness is linked by file # to the Ergomed deal for 375k shares) and @ImmxBeliever BLOCKS ME! Is that bc he doesn’t want accurate info or bc he doesn’t want me TO SEE (or respond) to the BS he constantly spews on this board???
1 · Reply
ImmxBeliever
ImmxBeliever Dec. 5 at 12:14 AM
$CVM @Easygoer712 You may think a few of us are short or have a vengeance toward cvm Thats your prerogative. You will see soon we were always right Best wishes
0 · Reply
ImmxBeliever
ImmxBeliever Dec. 4 at 11:45 PM
$CVM @Easygoer712 FROM Ai regarding the filing Link below SEC just posted a Notice of Effectiveness for CEL-SCI’s S-3 (effective 12/3 at 4pm). This means the company’s shelf registration is now active, giving them the ability to issue shares or raise capital without further SEC review. Not an offering by itself — but it opens the door for one. Worth watching near-term for any follow-up filings, prospectus supplements, or financing moves. EC just posted a Notice of Effectiveness for CEL-SCI’s S-3 (effective 12/3 at 4pm). This means the company’s shelf registration is now active, giving them the ability to issue shares or raise capital without further SEC review. Not an offering by itself — but it opens the door for one. Worth watching near-term for any follow-up filings, prospectus supplements, or financing moves. Tomorrow we ride!
1 · Reply
ImmxBeliever
ImmxBeliever Dec. 4 at 11:28 PM
$CVM Its not an error. Its complete and accurate It so funny how they cant read
0 · Reply
Easygoer712
Easygoer712 Dec. 4 at 10:40 PM
$CVM @BioGLovesMe @DeepThought i think Geert was drunk with excitement at the SFDA approval and clicked the SEC filing too early. He is a BOZO
3 · Reply
Easygoer712
Easygoer712 Dec. 4 at 10:33 PM
$CVM something’s about to happen. 4 pm and then a blank
1 · Reply
stinger69
stinger69 Dec. 4 at 9:53 PM
$CVM nothing attached to that SEC filing? Is news coming for SFDA ? 🤞
2 · Reply
DeepThought
DeepThought Dec. 4 at 8:19 PM
$CVM Short? Could hurt!
0 · Reply
Bjfrank87
Bjfrank87 Dec. 4 at 7:54 PM
$CVM PR after hours today
1 · Reply
VRandAR
VRandAR Dec. 4 at 7:51 PM
$CVM
0 · Reply
ImmxBeliever
ImmxBeliever Dec. 4 at 6:04 PM
$CVM and there is folks He punts it another 23 days Then after 12/31, another punt you deserve to lose it all  Cheers
1 · Reply
ImmxBeliever
ImmxBeliever Dec. 4 at 6:03 PM
$CVM I told you he would move the goal post Sad and easy to predict
0 · Reply
Easygoer712
Easygoer712 Dec. 4 at 6:00 PM
$CVM Looks like I was wrong on this week getting news.... damn I should stick with Fantasy Football. My new end date for news....12/31/2025
1 · Reply